This study has been applied through a program suitable for the identification of those molecules with the highest chances to interact with a particular target protein.It is being used successfully in drug development for a variety of high impact diseases.The 2014 edition of the "Marató de TV3" was dedicated to research in cardiac diseases. The research has been co-directed by Eva Estébanez Perpiñá, IBUB researcher and Serra Hunter professor, together with Pablo Fuentes Prior researcher from IBB-Sant Pau, both members of the Research Group Bases Estructurals de Processos Fisiopatològics Fonamentals, recognized by the Generalitat de Catalunya, and from the Red Nacional de Receptors Nuclears (National Network of Nuclear Receptors) from the Ministry of Economy, Industry and Competitiveness., enables understanding the molecular bases of mutations detected in patients of prostate cancer and also in the ones with androgenic insensitivity syndrome (AIS), a disease caused by the mutations in the X chromosome that create a resistance to male hormones.The research has been protected by a patent application with the University of Barcelona, the Research Institute Foundation of the Santa Creu and Sant Pau Hospital, as co-owners.
Xavier Barril with Premi Senén Vilaró for the best innovation company.
Migraine is one of the most common neurological disorders and it affects 1 out of 7 people in the world.
Painful and incapacitating, it has multi-factor origins, with the participation of environmental triggering factors and several altered genes in each individual.
Opitz (University of Utah, United States), Giovanni Neri (Catholic University of the Sacred Heart, Italy) and a wide group of experts of the Center for Genomic Regulation (CRG) and the Department of Clinical and Molecular Genetics of the University Hospital Vall d’Hebron (VHIR). Martinez-Estrada, are developing basic biomedical research projects in cardiology with the support of Fundació la Marató de TV3. Subjects such as cardiac regeneration, the role of inflammation, cardiomiokines or heart development will be discussed at the symposium. A team led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) and the Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB Sant Pau) shows for the first time, the three-dimensional structure of the homodimeric androgen receptor ligand-binding domain, a structure that eluded researchers for years.
The research project on identifying new therapeutic targets to fight the mechanism of tumor progression, leaded by Marçal Pastor-Anglada, IBUB Director, have been awarded by the Fundación Ramón Areces. The mini-symposium on 3 March will provide an overview of this research, complemented by contributions from international experts in experimental research on cardiology such as Dr. Bayes-Genis, from the Hospital Germans Trias i Pujol, and Dr. This new structure of the nuclear receptor allows explaining more than forty mutations related to prostate cancer, one of the most common worldwide and especially in Catalonia, as well as known developing disorders such as the androgen insensitivity syndromes.